

Amendments To The Claims

1-59. (Canceled)

60. (Previously presented) A method for treating a B cell leukemia comprising administering a therapeutically effective amount of:

- (i) an anti CD20 antibody having B-cell depleting activity, or a fragment thereof having B-cell depleting activity; and
- (ii) an anti CD40L antibody that antagonizes interaction of CD40 and CD40L, or a fragment thereof that antagonizes interaction of CD40 and CD40L.

61-64. (Canceled)

65. (Previously presented) The method of claim 60 wherein said B cell leukemia is selected from the group consisting of chronic B cell leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and Burkitt's type leukemia.

66. (Previously presented) The method of claim 60 wherein said anti CD20 antibody is a humanized, primatized, or chimeric anti CD20 antibody.

67. (Previously presented) The method of claim 60 wherein said anti CD40L antibody is a humanized, primatized, or chimeric anti CD40L antibody.

68. (Previously presented) The method of claim 67 wherein said anti CD40L antibody is humanized MAb 89-76 or humanized MAb 24-31.

69. (Previously presented) The method of claim 60 wherein said anti-CD20 antibody is radiolabeled with ⁹⁰Y.

70. (Canceled)

71. (Previously presented) The method of claim 60, which further comprises administering at least one alkylating chemotherapeutic agent.

72. (Previously presented) The method of claim 71 wherein said alkylating chemotherapeutic agent is selected from the group consisting of cyclophosphamide, chlorambicil, procarbazine, and lomustine.

73-79. (Canceled)

80. (Previously presented) The method of claim 60 wherein the anti CD20 antibody is administered prior to the anti CD40L antibody.

81. (Previously presented) The method of claim 60 wherein the anti CD20 antibody is administered after the anti CD40L antibody.

82. (Previously presented) The method of claim 80 wherein the anti CD20 antibody is IDEC-C2B8 and the anti CD40L antibody is humanized MAb 24-31.

83. (Previously presented) The method of claim 81 wherein the anti CD20 antibody is IDEC-C2B8 and the anti CD40L antibody is humanized MAb 24-31.

84. (Previously presented) The method of claim 80 which further comprises administering at least one alkylating chemotherapeutic agent.

85. (Previously presented) The method of claim 81 which further comprises administering at least one alkylating chemotherapeutic agent.

86. (Previously presented) The method of claim 66 wherein said anti CD20 antibody is IDEC-C2B8.

87. (Previously presented) The method of claim 86 wherein said anti CD40L antibody is humanized MAb 24-31.

88. (Previously presented) The method of claim 68 wherein said anti CD40L antibody is humanized MAb 24-31.

89. (Previously presented) The method of claim 60, wherein a weekly dose of said anti CD20 antibody is 0.4 to 20 mg/kg body weight, and a dose of said anti CD40L antibody is 0.5 to 10 mg/kg body weight.

90. (Previously presented) The method of claim 69 wherein said anti-CD20 antibody that is radiolabeled with ⁹⁰Y is a non-chimeric murine antibody.

91. (Previously presented) The method of claim 84 wherein said alkylating chemotherapeutic agent is selected from the group consisting of cyclophosphamide, chlorambicil, procarbazine, and lomustine.

92. (Previously presented) The method of claim 85 wherein said alkylating chemotherapeutic agent is selected from the group consisting of cyclophosphamide, chlorambicil, procarbazine, and lomustine.

93. (Previously presented) A method for treating a B cell leukemia comprising administering a therapeutically effective amount of:

- (i) IDEC-C2B8, and
- (ii) humanized MAb 24-31.

94. (Previously presented) The method of claim 93 wherein IDEC-C2B8 is administered prior to humanized MAb 24-31.

95. (Previously presented) The method of claim 93, wherein a weekly dose of said IDEC-C2B8 is 0.4 to 20 mg/kg body weight, and a dose of said humanized MAb 24-31 is 0.5 to 10 mg/kg body weight.

96. (Previously presented) The method of claim 93 wherein said B cell leukemia is selected from the group consisting of chronic B cell leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and Burkitt's type leukemia.

97. (Previously presented) The method of claim 93 wherein IDEC-C2B8 is radiolabeled with ⁹⁰Y.

98. (Previously presented) The method of claim 93 which further comprises administering at least one alkylating chemotherapeutic agent.

99. (Previously presented) The method of claim 98 wherein said alkylating chemotherapeutic agent is selected from the group consisting of cyclophosphamide, chlorambicil, procarbazine, and lomustine.